8-K: Larimar Therapeutics Announces Positive Initial Data for Friedreich's Ataxia Treatment, Nomlabofusp

Larimar Therapeutics reported positive initial data from its long-term open label extension study of nomlabofusp, showing increased frataxin levels and early trends of clinical improvement in patients with Friedreich's ataxia.

Summary

• Larimar Therapeutics announced positive initial data from its ongoing open label extension (OLE) study of nomlabofusp, a potential treatment for Friedreich's ataxia (FA).
• The study evaluated daily subcutaneous injections of 25 mg of nomlabofusp in 14 participants for up to 260 days.
• Tissue frataxin (FXN) levels increased significantly, with mean levels rising from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90.
• Early trends towards improvement in clinical outcomes were observed at Day 90, including in modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), Modified Fatigue Impact Scale, and 9 Hole Peg Test.
• Pharmacokinetic (PK) data showed that nomlabofusp levels in plasma reached steady state by Day 30 with no further accumulation.
• The company has initiated dose escalation to 50 mg daily in the OLE for six participants.
• Screening of adolescents for a pediatric PK run-in study is ongoing, with dosing expected in early 2025.
• A global confirmatory/registration study is planned to begin in mid-2025.
• Larimar is targeting a Biologics License Application (BLA) submission in the second half of 2025 to support potential accelerated approval.
• The company has a strong balance sheet with $203.7 million in cash and investments as of September 30, 2024, projecting a cash runway into the second quarter of 2026.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data, a strong financial position, and a clear path forward for regulatory approval, indicating a high level of optimism for the company's prospects.

Positives

• Nomlabofusp demonstrated a favorable safety profile with long-term daily administration.
• The drug significantly increased and maintained tissue FXN levels over time.
• Early trends suggest potential clinical benefits across a broad spectrum of FA patients.
• The pharmacokinetic profile of nomlabofusp is consistent with previous studies.
• The company has a strong financial position with sufficient cash to fund operations into Q2 2026.
• Larimar is advancing discussions with the FDA for potential accelerated approval.
• The company is expanding clinical evaluation into adolescents and children.

Negatives

• Two participants experienced serious adverse events during the OLE study, although these resolved within 24 hours.
• The most common adverse events were injection site reactions, though most were mild and self-limited.

Risks

• The success of the clinical trials and regulatory approvals are not guaranteed.
• Preliminary clinical trial results may differ from final results.
• The FDA may not agree with Larimar's development strategy.
• The company's ability to raise capital and commercialize the drug is subject to market conditions and other factors.
• There are risks associated with manufacturing and scaling up production of nomlabofusp.
• Public health crises could impact clinical trials and operations.

Future Outlook

Larimar is focused on advancing the nomlabofusp program, including dose escalation, pediatric studies, and a global confirmatory study, with the goal of submitting a BLA in the second half of 2025 for potential accelerated approval. The company is also exploring additional applications of its intracellular delivery platform for other rare diseases.

Management Comments

• Carole Ben-Maimon, MD, President and CEO, stated that they are pleased with the advancement of the OLE study and encouraged by the early trends towards improvement in clinical outcomes.
• Dr. Ben-Maimon also mentioned that the long-term safety, PK, and FXN data will be used to support a potential accelerated approval using FXN as a novel surrogate endpoint.
• Dr. Rusty Clayton, Chief Medical Officer, noted that long-term dosing of nomlabofusp was generally well tolerated and that serious adverse events resolved quickly.
• Dr. Susan Perlman, a principal investigator, stated that increases in frataxin levels may lead to the slowing of disease progression.

Industry Context

This announcement is significant in the context of Friedreich's ataxia, a rare and progressive disease with limited treatment options. The positive data from Larimar's study suggests a potential new therapy that directly addresses the underlying frataxin deficiency, which is a key unmet need in the FA treatment landscape. The company's focus on accelerated approval also reflects the urgency in developing treatments for rare diseases.

Comparison to Industry Standards

• The current standard of care for Friedreich's ataxia primarily focuses on managing symptoms, with no approved therapies that directly address the underlying frataxin deficiency.
• Biogen's Omaveloxolone (SKYCLARYS) is approved for FA but works by modifying mitochondrial oxidative stress, not by increasing frataxin levels.
• Larimar's nomlabofusp is a protein replacement therapy designed to directly address the frataxin deficiency, which is a novel approach compared to other treatments in development.
• Other companies like PTC Therapeutics (Vatiquinone) and Design Therapeutics (DT-216P2) are exploring different mechanisms of action, such as 15-Lipoxygenase inhibition and gene expression regulation, respectively.
• Lexeo Therapeutics is developing a gene therapy (LX2006) for FA, which is a different approach than Larimar's protein replacement therapy.
• The increase in frataxin levels observed in Larimar's study is a key differentiator, as it directly targets the root cause of the disease, and the early trends in clinical outcomes are promising compared to the current standard of care.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical data and the company's strong financial position.
• Patients with Friedreich's ataxia and their families may have increased hope for a potential new treatment option.
• Employees of Larimar Therapeutics may be motivated by the progress of the clinical program.
• The positive results may attract potential collaborators and investors.

Next Steps

• Initiate dosing in the pediatric PK run-in study for adolescents in early 2025.
• Enroll children in the pediatric PK run-in study in the first half of 2025.
• Initiate the global confirmatory/registration study in mid-2025.
• Collect and analyze data from the 50 mg dose in the OLE study, expected mid-2025.
• Submit a BLA in the second half of 2025, pursuing accelerated approval.

Key Dates

Keywords

Friedreich's ataxia, nomlabofusp, frataxin, clinical trial, rare disease, biotechnology, FDA, accelerated approval, protein replacement therapy, subcutaneous injection